[go: up one dir, main page]

MX2019004763A - Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos. - Google Patents

Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos.

Info

Publication number
MX2019004763A
MX2019004763A MX2019004763A MX2019004763A MX2019004763A MX 2019004763 A MX2019004763 A MX 2019004763A MX 2019004763 A MX2019004763 A MX 2019004763A MX 2019004763 A MX2019004763 A MX 2019004763A MX 2019004763 A MX2019004763 A MX 2019004763A
Authority
MX
Mexico
Prior art keywords
psychiatric
treatment
cognitive disorders
combination treatments
imidazopyrazinones
Prior art date
Application number
MX2019004763A
Other languages
English (en)
Inventor
Kehler Jan
Juhl Karsten
Langgård Morten
Kyhn Rasmussen Lars
Jessing Mikkel
Jorge Vieira Vital Paulo
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2019004763A publication Critical patent/MX2019004763A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona tratamientos de combinación que comprenden la administración de compuestos que son inhibidores de la enzima PDE1 y otros compuestos útiles en el tratamiento de trastornos psiquiátricos y/o cognitivos tales como, por ejemplo, el trastorno por déficit de atención con hiperactividad (TDAH), depresión, ansiedad, narcolepsia, esquizofrenia, 5 deterioro cognitivo o deterioro cognitivo asociado con esquizofrenia (DCAE). Diferentes aspectos de la invención se refieren al uso combinado de dichos compuestos para el tratamiento de trastornos psiquiátricos y/o cognitivos. La presente invención también proporciona composiciones farmacéuticas que comprenden dichos inhibidores de la enzima PDE1 junto con otros compuestos útiles en el tratamiento de trastornos 10 psiquiátricos y/o cognitivos.
MX2019004763A 2016-10-28 2017-10-26 Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos. MX2019004763A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201600659 2016-10-28
PCT/EP2017/077497 WO2018078038A1 (en) 2016-10-28 2017-10-26 Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Publications (1)

Publication Number Publication Date
MX2019004763A true MX2019004763A (es) 2019-07-01

Family

ID=60186299

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004763A MX2019004763A (es) 2016-10-28 2017-10-26 Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos.

Country Status (30)

Country Link
US (1) US10905688B2 (es)
EP (1) EP3532064B1 (es)
JP (1) JP2019536762A (es)
KR (1) KR20190075068A (es)
CN (1) CN109803658A (es)
AR (1) AR109991A1 (es)
AU (1) AU2017350473A1 (es)
BR (1) BR112018013247A2 (es)
CA (1) CA3041607A1 (es)
CL (1) CL2019001091A1 (es)
CO (1) CO2019002909A2 (es)
CY (1) CY1123396T1 (es)
DK (1) DK3532064T3 (es)
ES (1) ES2816005T3 (es)
HR (1) HRP20201326T1 (es)
HU (1) HUE050403T2 (es)
IL (1) IL265635A (es)
LT (1) LT3532064T (es)
MA (1) MA46611B1 (es)
ME (1) ME03821B (es)
MX (1) MX2019004763A (es)
PL (1) PL3532064T3 (es)
PT (1) PT3532064T (es)
RS (1) RS60716B1 (es)
RU (1) RU2019109039A (es)
SG (1) SG11201903770UA (es)
SI (1) SI3532064T1 (es)
SM (1) SMT202000440T1 (es)
WO (1) WO2018078038A1 (es)
ZA (1) ZA201902091B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
KR20190075068A (ko) 2016-10-28 2019-06-28 하. 룬드벡 아크티에셀스카브 정신 및/또는 인지 장애의 치료를 위한 이미다조피라지논을 포함하는 병용 치료
WO2018078042A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
MY205011A (en) 2018-02-01 2024-09-27 Japan Tobacco Inc Nitrogen-containing heterocyclic amide compound and pharmaceutical use thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
WO2004099211A1 (de) 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
EP2805953B1 (en) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
EP2089034A4 (en) 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
AU2008249750B2 (en) 2007-05-11 2011-07-14 Pfizer Inc. Amino-heterocyclic compounds
WO2009068320A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
AU2009289240A1 (en) 2008-09-08 2010-03-11 Boehringer Ingelheim International Gmbh Pyrazolopyrimidines and their use for the treatment of CNS disorders
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
ES2764728T3 (es) 2010-08-12 2020-06-04 Lilly Co Eli Anticuerpos anti péptido Beta Amiloide N3pGlu y usos de los mismos
JP5855109B2 (ja) 2010-09-20 2016-02-09 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． イミダゾトリアジノン化合物
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
JP2015531401A (ja) * 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノン骨格を有するｐｄｅ９ｉ
BR112014018199A8 (pt) 2012-01-26 2021-03-02 H Lundbeck As inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
BR112014031731B1 (pt) 2012-06-18 2022-12-06 Dart Neuroscience (Cayman) Ltd Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos
TWI659032B (zh) 2013-03-15 2019-05-11 美商內胞醫療公司 有機化合物及其用途
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
US20170066741A1 (en) 2014-02-19 2017-03-09 H. Lundbeck A/S 2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
TW201629064A (zh) * 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
TW201639851A (zh) 2015-03-16 2016-11-16 大日本住友製藥股份有限公司 雙環咪唑衍生物
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
AR105668A1 (es) 2015-08-12 2017-10-25 H Lundbeck As 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CN105254635A (zh) * 2015-10-30 2016-01-20 中国药科大学 一类咪唑并吡嗪类化合物及其药物组合物和用途
AR107456A1 (es) 2016-02-12 2018-05-02 Lilly Co Eli Inhibidor de pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP2018076285A (ja) 2016-09-14 2018-05-17 大日本住友製薬株式会社 二環性イミダゾロ誘導体を含む医薬
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
KR20190075068A (ko) 2016-10-28 2019-06-28 하. 룬드벡 아크티에셀스카브 정신 및/또는 인지 장애의 치료를 위한 이미다조피라지논을 포함하는 병용 치료
WO2018078042A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones

Also Published As

Publication number Publication date
SI3532064T1 (sl) 2020-10-30
HRP20201326T1 (hr) 2020-11-27
CL2019001091A1 (es) 2019-07-05
ES2816005T3 (es) 2021-03-31
RU2019109039A3 (es) 2021-01-29
EP3532064B1 (en) 2020-07-29
RS60716B1 (sr) 2020-09-30
ZA201902091B (en) 2020-10-28
PL3532064T3 (pl) 2020-11-16
CO2019002909A2 (es) 2019-06-19
KR20190075068A (ko) 2019-06-28
RU2019109039A (ru) 2020-11-30
LT3532064T (lt) 2020-09-25
SG11201903770UA (en) 2019-05-30
MA46611A (fr) 2019-09-04
DK3532064T3 (da) 2020-08-24
AU2017350473A1 (en) 2019-04-18
CN109803658A (zh) 2019-05-24
SMT202000440T1 (it) 2020-09-10
JP2019536762A (ja) 2019-12-19
EP3532064A1 (en) 2019-09-04
MA46611B1 (fr) 2020-08-31
CY1123396T1 (el) 2021-12-31
ME03821B (me) 2021-04-20
WO2018078038A1 (en) 2018-05-03
PT3532064T (pt) 2020-09-03
US10905688B2 (en) 2021-02-02
IL265635A (en) 2019-05-30
CA3041607A1 (en) 2018-05-03
US20190282571A1 (en) 2019-09-19
HUE050403T2 (hu) 2020-12-28
BR112018013247A2 (pt) 2018-12-04
AR109991A1 (es) 2019-02-13

Similar Documents

Publication Publication Date Title
MX2019004763A (es) Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
CL2015002529A1 (es) Compuestos de tetrahidropirrolotiazina
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
EA201691134A1 (ru) Новые ингибиторы глутаминазы
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
EA202193044A2 (ru) Способы лечения таупатии
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX395572B (es) Anticuerpos anti-htra1 y metodos de uso de los mismos
MX394051B (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2017010841A (es) Composiciones mejoradas de perfume.
NO20180002A1 (en) Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2017008083A (es) Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa.